Aktis Oncology, Inc.
Aktis Oncology, Inc. (AKTS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · AKTS · as of Jun 9, 2026
Key Statistics
Explore Aktis Oncology, Inc. Data
akts stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 7 · Buy rate: 57.1%
The AKTS analyst consensus is Buy, based on ratings from 7 Wall Street analysts over the past 3 months. The average 12-month price target is $33.00, representing +73.96% upside from the current price of $18.97.
Stock Performance
Full HistoryAbout Aktis Oncology, Inc.
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein …
what is aktis oncology, inc. · akts stock overview · aktis oncology, inc. company profile · who is aktis oncology, inc. ceo · akts NASDAQ · aktis oncology, inc. headquarters · aktis oncology, inc. business segments
About Stock Overview & Key Data
Aktis Oncology, Inc. (AKTS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 9, 2026. As of the latest trading session, AKTS stock price is $18.97, with a market capitalization of $1.0B. The stock has returned -15.31% over the past 12 months and -15.31% year-to-date.
According to 7 Wall Street analysts, the consensus rating for Aktis Oncology, Inc. stock is Buy, with an average 12-month price target of $33.00. In fiscal year 2025, Aktis Oncology, Inc. reported revenue of $6.5M and net income of -$63.7M. For detailed data — including Aktis Oncology, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Aktis Oncology, Inc. (AKTS) stock price is $18.97. The stock is traded on NASDAQ under the ticker symbol AKTS. The 52-week range is $14.72 – $29.16.